Type 1 diabetes

Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials

Diabetes Obes MetabPublished Systematic review and meta-analysis of randomised trials

Pooled result · HbA1cResult — go to the resultMD −0.21 % 95% CI −0.36 to −0.06

Authors' conclusion

Our findings suggest that, in individuals with T1D, add-on therapy with GLP-1RAs does not confer significant benefits in terms of CGM metrics and is associated with a longer time below the target glycaemic range.

Study context

Population
Adults with T1D on insulin therapy; Randomized controlled trials (RCTs) from Medline, Cochrane Library and Google Scholar up to 27 May 2024
Participants
378 adults6 RCTs
Comparison
GLP-1 RA add-on to insulin vs placebo
Outcome
HbA1c
Methodological detailsrandom-effects meta-analysis, dual-independent study selection, data extraction and quality assessment
  • Random-effects meta-analysis
  • Dual-independent study selection, data extraction and quality assessment

Pooled result

As reported in the abstract

MD

−0.21 %

95% CI −0.36 to −0.06

P = 0.007

GLP-1RAsvs Placebo
MD −0.21 % (95% CI −0.36 to −0.06); P = 0.007

Further pooled results

OutcomeMD (%) (95% CI)P value
TIRSimilar TIR−0.22 (−2.39 to 1.95)P = 0.84
TAR−1.83 (−2.51 to −1.15)P < 0.001

Other secondary outcomes (MAGE, CONGA-60 min, mean daily glucose, CV, mean SD of weekly glucose)

Nonsignificant differences

Safety

OutcomeMD (%) (95% CI)P value
TBR1.13 (0.50–1.76)P < 0.001

Original publication

Effects of glucagon‐like peptide‐1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 30 September 2024. doi:10.1111/dom.15979

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.